Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone650-741-7700
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees171
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Global Blood Therapeutics (NASDAQ:GBT) Frequently Asked Questions
What is Global Blood Therapeutics' stock symbol?
Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."
How were Global Blood Therapeutics' earnings last quarter?
Global Blood Therapeutics Inc (NASDAQ:GBT) posted its quarterly earnings results on Wednesday, August, 7th. The company reported ($1.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.96) by $0.05. During the same quarter in the prior year, the company earned ($0.78) EPS. View Global Blood Therapeutics' Earnings History.
When is Global Blood Therapeutics' next earnings date?
What price target have analysts set for GBT?
12 brokers have issued 1-year price objectives for Global Blood Therapeutics' stock. Their forecasts range from $60.00 to $150.00. On average, they expect Global Blood Therapeutics' share price to reach $91.4545 in the next year. This suggests a possible upside of 95.6% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics.
What is the consensus analysts' recommendation for Global Blood Therapeutics?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics.
What are Wall Street analysts saying about Global Blood Therapeutics stock?
Here are some recent quotes from research analysts about Global Blood Therapeutics stock:
- 1. HC Wainwright analysts commented, "Our Buy rating and $150 PT are based on a DCF analysis, derived using a beta of 1.58, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 9.8%, and tax rate of 15% beginning in FY 2024. We estimate approximately 70K patients in U.S., 42K patients in the $60K U.S. and EU launch prices, respectively, a 2020 commercial launch, 70% compliance, and 23% gross-to-net. In 2022, we model global sales at roughly $820M and expect voxelotor peak sales of $2.7B during 2026, which assumes about 49% adoption across the developed nations, and a POS of 75%." (8/8/2019)
- 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (3/4/2019)
- 3. William Blair analysts commented, "We continue to view the stock as substantially de-risked with the completion of 24 weeks of therapy in the additional 118 enrolled patients in the Phase III HOPE study , publication of the HOPE Part A data set, and a pre-NDA meeting update in the first half as well as potential Subpart H filing in the second half as key catalysts for shares this year . We also see the company as a potential takeout candidate given the significant unmet medical need in sickle cell disease, the impressive data shown in patients with or without concomitant hydroxyurea, and the alignment of a once-daily , oral therapy dosed (potentially) in perpetuity with the large pharma commercial model. GBT remains our top pick for 2019." (1/30/2019)
- 4. Cantor Fitzgerald analysts commented, "Based on the existing clinical data, we believe voxelotor offers a compelling treatment option in SCD that lacks disease-modifying therapies. $96 price target is based on the combination of our estimate of the NPV of future cash flows from voxelotor in SCD, worth approximately $4.6 billion ($88/share), and our estimate of YE cash of $440 million ($8/share)." (10/17/2018)
Has Global Blood Therapeutics been receiving favorable news coverage?
Headlines about GBT stock have been trending positive on Tuesday, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Global Blood Therapeutics earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Global Blood Therapeutics.
Who are some of Global Blood Therapeutics' key competitors?
Some companies that are related to Global Blood Therapeutics include Array Biopharma (ARRY), Ionis Pharmaceuticals (IONS), Mylan (MYL), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), SAGE Therapeutics (SAGE), Catalent (CTLT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Teva Pharmaceutical Industries (TEVA), Perrigo (PRGO) and Dr.Reddy's Laboratories (RDY).
What other stocks do shareholders of Global Blood Therapeutics own?
Who are Global Blood Therapeutics' key executives?
Global Blood Therapeutics' management team includes the folowing people:
- Dr. Ted W. Love, Pres, CEO & Director (Age 60)
- Dr. Charles J. Homcy, Founder, Advisor & Director (Age 71)
- Mr. Jeffrey S. Farrow, Chief Financial Officer (Age 57)
- Mr. Peter Radovich, Sr. VP of Operations (Age 41)
- Dr. Hing Sham, Sr. VP of Research (Age 67)
When did Global Blood Therapeutics IPO?
(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.
Who are Global Blood Therapeutics' major shareholders?
Global Blood Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (9.62%), Vanguard Group Inc. (8.94%), BlackRock Inc. (7.47%), Price T Rowe Associates Inc. MD (6.96%), Bank of America Corp DE (5.45%) and Janus Henderson Group PLC (4.31%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Jung Choi, Lesley Ann Calhoun, Perceptive Advisors Llc and Peter Radovich. View Institutional Ownership Trends for Global Blood Therapeutics.
Which institutional investors are selling Global Blood Therapeutics stock?
GBT stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, Janus Henderson Group PLC, Janus Henderson Group PLC, First Midwest Bank Trust Division, Bank of New York Mellon Corp, Pictet Asset Management Ltd., Pictet Asset Management Ltd. and GW&K Investment Management LLC. View Insider Buying and Selling for Global Blood Therapeutics.
Which institutional investors are buying Global Blood Therapeutics stock?
GBT stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Vanguard Group Inc., Eagle Asset Management Inc., Bank of America Corp DE, Luminus Management LLC, Carillon Tower Advisers Inc., Perceptive Advisors LLC and Asymmetry Capital Management L.P.. View Insider Buying and Selling for Global Blood Therapeutics.
How do I buy shares of Global Blood Therapeutics?
Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Global Blood Therapeutics' stock price today?
One share of GBT stock can currently be purchased for approximately $46.76.
How big of a company is Global Blood Therapeutics?
Global Blood Therapeutics has a market capitalization of $2.81 billion. The company earns $-174,190,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.View Additional Information About Global Blood Therapeutics.
What is Global Blood Therapeutics' official website?
How can I contact Global Blood Therapeutics?
Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]
MarketBeat Community Rating for Global Blood Therapeutics (NASDAQ GBT)
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe GBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
